Highest Efficacy of Dual Antiplatelet Therapy After Carotid Artery Stenting in High Bleeding Risk Patients

• Study Design CHET is a prospective, multicenter, randomized, open-label, superiority trial conducted at comprehensive stroke centers in the Republic of Korea. Endpoint adjudication is performed by an independent Clinical Event Assessment Committee (CEAC) blinded to treatment allocation, and safety is overseen by an independent Data Safety Monitoring Board (DSMB).
• Randomization Patients who complete the 30-day enrichment period without a net clinical event are randomized 1:1 via a centralized, secure web-based system using permuted blocks of variable size, stratified by participating center. The allocation sequence and block sizes are concealed from investigators to maintain allocation concealment.
• Treatment Arms (11 months following randomization) Experimental arm (SAPT): Single antiplatelet therapy with either aspirin 100 mg once daily or clopidogrel 75 mg once daily, at the treating physician's discretion, for 11 months.

Active comparator arm (DAPT): Continued dual antiplatelet therapy with aspirin 100 mg once daily and clopidogrel 75 mg once daily for 11 months.

• Follow-up Scheduled outpatient visits are performed at 5 months and 11 months after randomization (corresponding to approximately 6 and 12 months after CAS). Following the 11-month visit, participants are followed annually through outpatient visits or telephone contact until study completion in December 2029 to capture long-term clinical events. Antiplatelet therapy after the randomized 11-month treatment period is at the discretion of the treating physician and is not mandated by the protocol.
• Endpoints 1) Primary safety endpoint: Clinically significant bleeding (BARC type 2, 3, or 5) occurring from 30 days to 12 months after CAS.

• Key secondary efficacy endpoint: Net clinical outcome, defined as the composite of nonfatal stroke, nonfatal myocardial infarction, cardiovascular death, and major bleeding (BARC type 3 or 5), occurring from 30 days to 12 months after CAS, evaluated under a noninferiority hypothesis (margin 5%, one-sided alpha 2.5%).

Inclusion criteria

• Patients ≥19 years
• Symptomatic patients with carotid artery stenosis* greater than 50% and asymptomatic patients with carotid artery stenosis* greater than 70% who are scheduled to undergo or who have undergone carotid artery stenting
• High bleeding risk is defined as a Bleeding Academic Research Consortium type 3 or 5 bleeding risk of ≥4% at 1 year or a risk of an intracranial hemorrhage (ICH) of ≥1% at 1 year, Patients who meet at least one of the criteria for high bleeding risk** below

• The degree of stenosis is determined using the method performed in the North American Symptomatic Carotid Endarterectomy Trial.

• Criteria for high bleeding risk (≥ 1)

• Incidence of non-access site bleeding within 12 months prior to stenting (gastrointestinal tract or hematuria)
• Presence of BARC type 3 or 5 bleeding regardless of the onset time, but the cause has not been completely cured.
• Adults aged ≥75 years
• Thrombocytopenia < 100,000/mm3 (based on the screening test)
• Blood clotting disorders that increase bleeding (Von Willebrand disease, factor VII, VIII, IX, and XI deficiency)
• Patients with anemia defined as hemoglobin <12g/dL in men and <11g/dL in women or patients who donated blood within 4 weeks (based on the screening test)
• Patients received steroids or NSAIDs for ≥4 weeks
• Patients with active malignancy (except for nonmelanoma skin cancer)
• Renal disease (dialysis, transplantation, Estimated Glomerular Filtration Rate < 60ml/min per 1.73m2)
• Liver disease (cirrhosis with portal hypertension)
• Cerebral microbleeds ≥ 5
• Stroke or transient ischemic attacks within 6 months or Transient amaurosis fugax
• Incidence of nontraumatic intracerebral hemorrhage regardless of duration or incidence of traumatic intracerebral hemorrhage within 12 months

Exclusion criteria

• Incidence of net clinical events, including cardiovascular and cerebrovascular accidents or major bleeding events, within 30 days following carotid artery stenting
• Discontinuation of dual antiplatelet therapy within 30 days after carotid stent implantation (However, use of a single antiplatelet therapy within 7 days due to acute infection and trauma is allowed, but dual antiplatelet therapy must be administered at 28 to 30 days after carotid stent implantation)
• Coronary artery stenting or other vascular stenting or vascular recanalization within 1 year (Revascularization surgery that requires CABG(Coronary Artery Bypass Graft) and other dual antiplatelet therapy)
• Aspirin or clopidogrel hypersensitivity
• Pregnant or breastfeeding women (Women of childbearing need to check for pregnancy using urine or blood tests before enrollment, and use appropriate contraception methods during the clinical trial period)
• Patients requiring anticoagulation for ≥12 months
• Patients requiring administration of other antiplatelet therapies
• Patients who are participating in another intervention clinical trial